Hypera SA (Brazil) Performance
| HYPE3 Stock | BRL 19.65 0.34 1.70% |
The company retains a Market Volatility (i.e., Beta) of -0.57, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Hypera SA are expected to decrease at a much lower rate. During the bear market, Hypera SA is likely to outperform the market. At this point, Hypera SA has a negative expected return of -0.53%. Please make sure to check out Hypera SA's value at risk, skewness, and the relationship between the maximum drawdown and potential upside , to decide if Hypera SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hypera SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 4.7 B | |
| Total Cashflows From Investing Activities | -4.4 B |
Hypera |
Hypera SA Relative Risk vs. Return Landscape
If you would invest 2,795 in Hypera SA on August 31, 2024 and sell it today you would lose (830.00) from holding Hypera SA or give up 29.7% of portfolio value over 90 days. Hypera SA is generating negative expected returns and assumes 2.4249% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than Hypera, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Hypera SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hypera SA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hypera SA, and traders can use it to determine the average amount a Hypera SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2179
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HYPE3 |
Estimated Market Risk
| 2.42 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hypera SA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hypera SA by adding Hypera SA to a well-diversified portfolio.
Hypera SA Fundamentals Growth
Hypera Stock prices reflect investors' perceptions of the future prospects and financial health of Hypera SA, and Hypera SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hypera Stock performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0686 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 33.47 B | |||
| Shares Outstanding | 631.94 M | |||
| Price To Earning | 13.10 X | |||
| Price To Book | 2.55 X | |||
| Price To Sales | 3.79 X | |||
| Revenue | 5.94 B | |||
| EBITDA | 2.16 B | |||
| Cash And Equivalents | 2.24 B | |||
| Cash Per Share | 3.24 X | |||
| Total Debt | 6.85 B | |||
| Debt To Equity | 0.70 % | |||
| Book Value Per Share | 16.57 X | |||
| Cash Flow From Operations | 1.4 B | |||
| Earnings Per Share | 2.57 X | |||
| Total Asset | 19.82 B | |||
| Retained Earnings | 2.62 B | |||
| Current Asset | 6.68 B | |||
| Current Liabilities | 1.63 B | |||
About Hypera SA Performance
Assessing Hypera SA's fundamental ratios provides investors with valuable insights into Hypera SA's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Hypera SA is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. Hypera S.A. was founded in 2001 and is headquartered in So Paulo, Brazil. HYPERA ON operates under Drug ManufacturersSpecialty Generic classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 8918 people.Things to note about Hypera SA performance evaluation
Checking the ongoing alerts about Hypera SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hypera SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hypera SA generated a negative expected return over the last 90 days | |
| About 36.0% of the company shares are held by company insiders |
- Analyzing Hypera SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hypera SA's stock is overvalued or undervalued compared to its peers.
- Examining Hypera SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hypera SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hypera SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hypera SA's stock. These opinions can provide insight into Hypera SA's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hypera Stock Analysis
When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.